Read more about BBCR’s Streamlined Clinical Development Strategies in DigiTech Insight
Tagged: Candida Fratazzi
We are excited about the recognition by the DIGITECH insight magazine that included the BBCR’s proprietary SCIO process within the top 10 innovations in drug development for 2022.
February 9th, 2022 | Candida Fratazzi
Categories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- BBCR brings deep expertise in early-stage development, including Phase 1 and Phase 2 process and strategy, spanning pre-clinical work through pre-IND. Our early drug development capabilities encompass clinical strategy and planning, including the creation of target product profiles and the design of clinical protocols.
- BBCR partners with clients to identify, develop, and advance a product’s unique strengths from early concept through to market. Our consultancy is grounded in deep expertise across cell, biologic, and gene therapies, with a particular focus on rare disease.
- BBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work collaboratively with a product developer on the best plan to market. To learn more, visit bbcrconsulting.com.
- Drug repurposing accelerates the path from discovery to the clinic, offering particular promise for rare, neglected, oncologic, and neurodegenerative diseases. Learn how we can help at bbcrconsulting.com
- Is Your Drug Development Strategy Built for Tomorrow’s Success?